INTRODUCTION
Cannabis is the most commonly used drug among individuals with alcohol use disorders (AUD), with almost a quarter of individuals with past-year AUD reporting concurrent cannabis use [1] . Adolescent and young adult cannabis use has been linked to increased risk of AUD later in life [2] , and international studies have shown significant associations between cannabis use and AUD [3] [4] [5] . Concurrent use of marijuana and alcohol is associated with heavy episodic drinking, and the combined use of cannabis and alcohol may lead to more substance use and related problems compared to the use of alcohol alone [6] [7] [8] . Cannabis use has been examined as a predictor of substance use outcomes in a few treatment studies [9, 10] , and was found to have a deleterious impact.
However, evidence regarding the impact of cannabis use on alcohol consumption specifically among those in treatment for AUD remains sparse. Co-occurring drug use (including drugs other than cannabis) and alcohol use more broadly can impact the treatment of substance use disorders negatively [11] . Recent results from the National Epidemiological Study of Alcohol Use and Related Disorders (NESARC; wave 1, 2001-01; wave 2, 2004-05) show that among adults with a history of AUD, any cannabis use at wave 1 was related to 1.74 times the odds of AUD persistence at wave 2 when compared to no cannabis use [12] . Cannabis users who are also heavy drinkers report higher alcohol use, as well as more negative alcohol-related consequences [13] . In a sample of psychiatric treatment-seekers with AUD, cannabis use was related to an increased likelihood of alcohol relapse and decreased likelihood of stable abstinence [9] . Furthermore, the odds of alcohol dependence are substantially higher among those with cannabis dependence [12, 14, 15] , suggesting that hazardous alcohol use may increase as cannabis use increases. Results from a clinical trial which tested the effectiveness of chronic disease management and examined the relationship between cannabis use and the odds of abstinence 3, 6 and 12 months later showed that any cannabis use in the past 30 days at study entry was related to a 27% reduction in the odds of abstinence from drug and heavy alcohol use at later time-points [10] .
Few experimental studies have examined directly the interactions between alcohol and cannabis. One experimental study of 16 male concurrent alcohol/cannabis users showed that when subjected to conditions in which alcohol only, cannabis only or both alcohol and cannabis were available, participants tended to reduce alcohol intake when cannabis was also available (compared to not) [16] . A more recent laboratory study examined whether combinations of ethanol and Δ9-tetrahydrocannabinol (THC, one of the primary psychoactive compounds in cannabis) act synergistically on physiological and subjective measures; results showed that while THC alone did not affect ratings of 'wanting more' THC, THC weakened the effects of ethanol-only administration on increased desire for alcohol [17] . Furthermore, and contrary to what was hypothesized originally, cannabis and alcohol did not act additively or multiplicatively on any measures, which included heart rate, blood pressure, blood alcohol concentration and subjective drug effects such as hunger and sedation [17] . Conversely, a review regarding the combined effects of cannabis and alcohol concluded that compared to either substance alone, the combination may have the strongest effects in terms of impaired driving tasks, subjective sensations and physiological measures, such as heart rate [18] . Physiologically, while smoking cannabis may slow absorption of alcohol, which then reduces alcoholˈs psychoactive effects, plasma THC levels can be enhanced if alcohol is consumed immediately after smoking cannabis [19, 20] . Thus, cannabis combined with alcohol can lead to greater impairment than ingestion of either substance alone.
Despite some evidence that cannabis use impacts alcohol use severity adversely, there are a number of contradictory findings from case report and correlational studies suggesting that cannabis can substitute for alcohol and reduce drinking [21] . High rates of cannabis substitution for alcohol have been reported by medical cannabis patients and their doctors [22] [23] [24] [25] , although results are limited by retrospective self-report and selection bias. A 30-year prospective study of alcohol abusers showed that almost half maintained a year of alcohol abstinence, with some claiming to substitute cannabis for alcohol [26] . Some even propose that medical cannabis could help individuals with AUD reduce drinking [22] [23] [24] ; however, these recommendations are based upon retrospective data, highlighting the need for more rigorous research in this area.
Rationale for current study
Collectively, the literature indicates that marijuana use is linked strongly with alcohol use; however, the evidence on whether cannabis users reduce or increase alcohol use when using or abstaining from cannabis is mixed. The mixed evidence may be explained partially by the heterogeneous samples (e.g. general population versus clinical samples), and/or variation in assessments of frequency of use (e.g. dichotomous versus continuous measures). Furthermore, no prior study has examined cannabis use during AUD treatment, and findings from general population or non-clinical studies are not necessarily generalizable to individuals who are currently in treatment for AUD. The current study builds upon previous findings by (1) restricting the sample to individuals currently in treatment for AUD and (2) examining use frequency categories, which is a more nuanced and potentially more powerful measure than dichotomized cannabis use and prevalence variables. Specifically, the aims of this study are: (1) to compare posttreatment alcohol use outcomes between those who use cannabis and those who abstain from cannabis during treatment for AUD; and (2) to examine potential cannabis use thresholds by comparing post-treatment alcohol use outcomes between four frequency groups of cannabis users and cannabis abstainers.
METHODS AND STATISTICS

Sample
For a detailed description of the Combined Pharmacotherapies and Behavioral Interventions (COMBINE) study, please see Anton et al. [27, 28] . Briefly, the COMBINE study was a large (n = 1383), multi-site randomized control trial in which newly alcohol-abstinent alcohol-dependent participants received one of four medication regimens (placebo, naltrexone, acamprosate or naltrexone + acamprosate) either with or without a behavioral intervention, for a total of eight possible treatments including medication. The ninth and final group received the behavioral intervention only, without any placebo or active medication. The COMBINE data span 68 weeks with measures at baseline, and 4, 8, 16 (end of treatment), 26, 52 and 68 weeks [27, 28] . Current dependence upon other psychoactive substances, except for cannabis and nicotine, resulted in exclusion for participation in the COMBINE Study.
Design
We performed secondary analyses of the COMBINE study, comparing longitudinal drinking data between those who used cannabis versus those who abstained during the COMBINE treatment period. In order to derive a potential threshold for cannabis use, we also compared posttreatment alcohol use outcomes between groups based on quartiles of cannabis use frequency and cannabis abstainers.
Measures
Exposures/key predictors
The exposures, any cannabis use during treatment (0 = none, 1 = at least one day) and quartiles of days of cannabis use during treatment were calculated from Form-90 [27, 28] ; if the individual had used cannabis on any one day between baseline and the last day of treatment (16 weeks or 112 days post-baseline), then they were considered a '1'. Quartiles of days of cannabis use were based on the distribution of the percentage of days of cannabis use among users only. Specifically, those in the lowest quartile, Q1, used approximately1-4% of days, or 1-4 days during treatment; the second quartile, Q2, used approximately5-8% of days, or 5-9 days during treatment; the third quartile used approximately 8-39% of days, or 10-44 days during treatment; and the highest quartile, Q4, used approximately 40-100% of days, or 45-112 days of treatment.
Outcomes
The first outcome, percentage of days abstinent (PDA), was the proportion of days abstinent between baseline and 16 weeks (end of treatment) as well as between 16 and 68 weeks (1 year post-treatment). The second outcome, drinks per drinking day (DPDD), was the average number of drinks consumed on days that drinking occurred. The final outcome of interest, percentage of days heavy drinking (PHD), was the proportion of days when more than four or five drinks were consumed by women/men, respectively. Drinks per drinking day and PHD were also measured at 16 and 68 weeks. All outcomes were calculated using Form-90 [27, 28] .
Covariates
All analyses controlled for age (years), gender, education (years), employment, income, marital status, race/ ethnicity, baseline Alcohol Dependence Severity (maximum possible score = 47) [27] , baseline PDA, baseline DPDD, baseline PHD, any nicotine use, any other drug use, COM-BINE treatment assignment and COMBINE treatment site; these covariates have been shown to relate to cannabis and/or alcohol use in prior studies. Race/ethnicity was self-reported by participants in accordance with National Institutes of Health guidelines. Responses were categorized as non-Hispanic black, non-Hispanic white, Hispanic or other in order to be consistent with the original COMBINE study. Other drug use was based on whether participants answered 'yes' to using any of the following during treatment: sedatives/tranquilizers, hypnotics, steroids, amphetamines, cocaine, hallucinogens, inhalants, opiates or unspecified other drugs.
Statistical methods
We assessed whether cannabis use was related to PDA, DPDD and PHD at the end of treatment (16 weeks) and 1 year post-treatment (68 weeks) using multi-level linear regression models with random slopes and intercepts for COMBINE treatment site; random effects were included to adjust for clustering as well as potential heterogeneity of cannabis effects across locations. Model fit statistics indicated that the mixed model with both random slopes and intercepts fitted best compared to random-intercept only and single-level linear models. The covariates described in the Covariates section were included in all models, and all analyses were performed in Stata version 13.
RESULTS
Sample characteristics
Overall, the sample was mainly male, non-Hispanic white and employed, with an average age of 44.4 years ( Table 1) . Table 1 also displays demographics and substance use characteristics of the cannabis user (those who used cannabis during treatment) and abstainer (those who did not use cannabis during treatment) subgroups. Users and abstainers differed significantly (P < 0.05) in terms of gender, age, education, income, marital status and alcohol dependence severity; specifically, users tended to be younger, less educated, lower-income, less likely to be married/cohabitating and less likely to be female. In terms of substance use, cannabis users had higher alcohol dependence severity, were more likely to use nicotine during treatment and were more likely to use other drugs during treatment. Users and abstainers did not differ significantly in terms of baseline past 90-day percentage of days abstinent from alcohol, drinks per drinking day or percentage of days heavy drinking. Table 2 displays results from the first set of regressions, which examined the relationship between any cannabis use during treatment and 16-week (end of treatment) and 68-week (1 year post-treatment) PDA. The first two columns show that cannabis use was related significantly (P < 0.01) to lower PDA at end of treatment, in both the unadjusted and adjusted models. In the unadjusted model, the association appeared to persist until 68 weeks (P < 0.05), but weakened when controlling for covariates. Any cannabis use during treatment was not related to DPDD or PHD at either 16 or 68 weeks (results not shown).
Any cannabis use during treatment
Regarding other correlates of PDA, non-Hispanic African Americans had higher PDA than non-Hispanic whites at both 16 and 68 weeks, while those who were not married had higher PDA at 68 weeks than those who were married. More severe alcohol dependence was not associated with PDA, although baseline PDA and PHD were (P < 0.01). Participants assigned to COMBINE treatment groups who received naltrexone, combined behavioral intervention (CBI) and/or both naltrexone and CBI generally had higher PDA compared to the placebo-only group at both 16 and 68 weeks, although these associations were not always significant at the P < 0.05 level. Most notably, any other drug use was a consistently stronger predictor of PDA than any cannabis use; post-hoc Wald and delta method-based tests of equality showed that the coefficient for other drug use was significantly larger than the Comparison of means between cannabis users and abstainers. Bold type indicates statistical significance. *P < 0.05; ***P < 0.001; CBI = combined behavioral intervention; SE = standard error. All models include random slopes and intercepts for treatment site. COMBINE = Combined Pharmacotherapies and Behavioral Interventions; CBI = combined behavioral intervention; PDA = percentage of days abstinent. Bold type indicates statistical significance, P < 0.05. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.10. SCID = Structured Clinical Interview and Diagnosis.
coefficient for cannabis use at both time-points (one-sided P < 0.10).
Quartiles of cannabis use during treatment
The second set of analyses compared quartiles of days of cannabis use during treatment to the referent group of cannabis abstainers (Table 3) . Only the second quartile of cannabis users, those who used approximately 5-8% or 5-9 days during treatment (approximately 1-2×/ month) had significantly lower PDA than cannabis abstainers; although effects were stronger in unadjusted models, they retained significance in models adjusted for covariates and persisted throughout 1 year post-treatment. Compared to no cannabis use, none of the cannabis use quartiles were associated with DPDD or PHD at either 16 or 68 weeks (results not shown). The pattern of associations between other covariates and drinking outcomes was almost identical to those described above, both in terms of significance and magnitude.
DISCUSSION
The results show that, compared to no cannabis use, any cannabis use during treatment for AUD was related to reduced alcohol abstinence at end of treatment; specifically, each additional day of cannabis use was associated with approximately 4-5 fewer days of abstinence from alcohol. However, when attempting to derive a threshold of cannabis use, the examination of cannabis quartiles demonstrated that the relationship between cannabis and alcohol use is more nuanced, and may depend more upon frequency than the simple presence of use; only the second quartile of cannabis use appeared to have significantly lower PDA than cannabis abstainers, with the first, third and fourth quartiles showing no significant differences. Cannabis use was not related to drinks per drinking day or heavy drinking days at either time-point. Unexpectedly, we found that being unmarried (versus married) was associated with approximately 5 more abstinent days 1 year post-treatment, while being African American or Hispanic (versus white) was associated with approximately 8 more abstinent days at end of treatment and 11 more abstinent days 1 year post-treatment. Post-hoc analyses comparing alcohol use severity, prevalence of other drug use, prevalence of cannabis use and frequency of cannabis use across races and marital status did not explain the unanticipated findings. However, a recent review and summary of NESARC findings concluded that African Americans and Hispanics had lower risk of SUD than whites, signifying that this 'paradox' has been observed in the general population [29] . Although we did not have any a priori hypotheses regarding other drug use, other drug use appears to be a stronger predictor of alcohol outcomes than cannabis use in this sample. Higher rates of other drug use (opiates, sedatives and stimulants) have been found among individuals with AUD compared to those without [30] , and other drug use can exacerbate treatment outcomes [11] . Nevertheless, cannabis use remained a significant predictor of alcohol use even when controlling for other drug use; this suggests that all drugs, including cannabis, might best be avoided if the ultimate goal is alcohol abstinence.
The current findings support those from the clinical trial of chronic disease management, which found that cannabis use in individuals with AUD was linked with reduced odds of successfully achieving abstinence from alcohol [10] . Similarly, post-discharge cannabis use among participants with AUD in in-patient psychiatric/substance abuse treatment has been shown to be related to reduced likelihood of stable remission from any substance use [9] . In a randomized trial of treatments for cigarette smoking cessation in heavy drinkers, weekly marijuana users actually decreased their drinking at a faster rate than non-users at the 8-week follow-up [31] ; however, weekly cannabis users also cut down their cannabis use steadily (at 8-, 16-and 26-week follow-ups) by more than 24%, which suggests that reduced cannabis use can lead to better alcohol outcomes.
Conversely, when examining more detailed levels of cannabis use relative to non-use through the analyses of quartiles, the findings in relation to alcohol outcomes do not appear to be linear. Unexpectedly, only the second quartile of cannabis use (using approximately 1-2×/month) was related to lower PDA, while the highest levels of cannabis use (using 3×/month or more) did not differ significantly in PDA compared to cannabis abstainers. Although the COMBINE data are not detailed enough to discern whether participants were using alcohol and cannabis concurrently versus separately, there may be a non-linear relationship between cannabis and alcohol use driven by individuals who were substituting cannabis for alcohol by using cannabis more frequently and alcohol less frequently.
A number of observational studies of individuals with AUD suggest that cannabis substitution for alcohol does occur. A within-subjects study of daily cannabis users not trying to change cannabis consumption examined whether cannabis abstinence would be related to changes in alcohol and other drug use [32] . Controlled abstinence from cannabis was indeed linked significantly with increased alcohol consumption (by 52%) and alcohol craving among individuals with past history of AUD but not those without past AUD (3% increase), suggesting substitution among those with past alcohol-related problems [32] . Cannabis substitution for alcohol has also been observed among medical cannabis patients with alcohol problems [21, 24, 25, 33] , although these studies are However, any speculation regarding substitution/ complementarity is limited by the nature of the data in that it is unknown whether participants were using cannabis on the actual days that they were drinking. To date, the bulk of published literature regarding event-level alcohol and cannabis use appears to focus on the relationship between substance use and sexual risk behaviors [34] [35] [36] [37] [38] . To our knowledge, no prior study has collected daily cannabis and alcohol use data from individuals in AUD treatment. Finer-grained, event-level data are needed in order to assess whether cannabis and alcohol act as substitutes or complements among individuals in treatment for AUD. Ongoing research will also examine moderators (effect modifiers) and mediators (mechanisms) of the relationship between cannabis use and alcohol outcomes and focus on understanding which subgroups, if any, are more prone to substitution versus complementarity. Future analyses will also include studying the costs and benefits of attending to cannabis use during AUD treatment, as this information is absolutely crucial for making informed treatment recommendations.
While the current findings are novel, the results are preliminary and require further confirmation and replication. Therefore, clinical implications must be limited to recommendations of avoiding using cannabis during alcohol treatment, as any cannabis use versus non-use appears to be linked with worse clinical outcomes. For cannabis users who are not motivated for abstinence from cannabis but may be contemplating reducing frequency of use, more research is needed to recommend a specific threshold at which alcohol treatment outcomes are not compromised by cannabis use. However, the set of results highlights two critical issues. First, cannabis use is not an 'all or nothing' phenomenon for individuals in treatment for AUD, and broadly saying that all levels of cannabis use exacerbate alcohol use may be misleading. Secondly, and related to the first point, the relationship between cannabis and alcohol is most certainly nuanced [33] , and probably non-linear; this underscores the importance of identifying how individuals use cannabis and alcohol simultaneously versus separately, especially as concurrent users are at highest risk of alcohol-related problems compared to both those who use the two substances separately and those who use alcohol only [8] . An event-level analysis of cannabis and alcohol use data can potentially address this limitation by examining situational factors in a natural setting. All models include random slopes and intercepts for treatment site. COMBINE = Combined Pharmacotherapies and Behavioral Interventions; CBI = combined behavioral intervention; PDA = percentage of days abstinent. Bold type indicates statistical significance, P < 0.05. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.10. SCID = Structured Clinical Interview and Diagnosis.
